Cargando…

A potential primary endpoint for clinical trials in glaucoma neuroprotection

The purpose of this retrospective, longitudinal study is to evaluate the relationship between MD slope from visual field tests collected over a short period of time (2 years) and the current United States’ Food and Drug Administration (FDA) recommended endpoints for visual field outcomes. If this co...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Moraes, Carlos Gustavo, Lane, Keith J., Wang, Xiao, Liebmann, Jeffrey M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154412/ https://www.ncbi.nlm.nih.gov/pubmed/37130950 http://dx.doi.org/10.1038/s41598-023-34009-x

Ejemplares similares

Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma
por: Montesano, Giovanni, et al.
Publicado: (2023)

Technology and the Glaucoma Suspect
por: Blumberg, Dana M., et al.
Publicado: (2016)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

Neuroprotection in glaucoma
por: Vasudevan, Sushil K, et al.
Publicado: (2011)

Neuroprotection in Glaucoma
por: Nilforushan, Naveed
Publicado: (2012)

Neuroprotection in Glaucoma
por: Doozandeh, Azadeh, et al.
Publicado: (2016)

Neuroprotection in glaucoma
por: Vishwaraj, C R, et al.
Publicado: (2022)

Potential of patient-reported outcomes as nonprimary endpoints in clinical trials
por: Gnanasakthy, Ari, et al.
Publicado: (2013)

Choosing primary endpoints for clinical trials of health care interventions
por: McLeod, Charlie, et al.
Publicado: (2019)

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
por: Isaacs, James, et al.
Publicado: (2022)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Neuroimaging as a Selection Tool and Endpoint in Clinical and Pre-clinical Trials
por: Muir, Keith W., et al.
Publicado: (2016)

Neurodegeneration and Neuroprotection in Glaucoma
por: Gauthier, Angela C., et al.
Publicado: (2016)

Neuroprotective therapies for glaucoma
por: Song, Wei, et al.
Publicado: (2015)

Neuroprotection in glaucoma-electrophysiology
por: Lešták, Ján, et al.
Publicado: (2020)

Neuroprotection in Glaucoma: Basic Aspects and Clinical Relevance
por: Kuo, Che-Yuan, et al.
Publicado: (2022)

Commentary on: A call for better reporting of trials using surrogate primary endpoints
por: Cummings, Jeffrey
Publicado: (2022)

The Importance of Endpoints in Oncology Clinical Trials
por: Faiman, Beth
Publicado: (2023)

Sample Size Requirements of Glaucoma Clinical Trials When Using Combined Optical Coherence Tomography and Visual Field Endpoints
por: Wu, Zhichao, et al.
Publicado: (2019)

Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials
por: Vaanholt, Melissa C.W., et al.
Publicado: (2018)

A Single Wide-Field OCT Protocol Can Provide Compelling Information for the Diagnosis of Early Glaucoma
por: Hood, Donald C., et al.
Publicado: (2016)

Immune maintenance in glaucoma: boosting the body’s own neuroprotective potential
por: Schwartz, Michal, et al.
Publicado: (2009)

Current perspective of neuroprotection and glaucoma
por: Tian, Kailin, et al.
Publicado: (2015)

Neuroprotective agents in the management of glaucoma
por: Nucci, C., et al.
Publicado: (2018)

Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery
por: Douin, David J., et al.
Publicado: (2022)

Individualized Glaucoma Change Detection Using Deep Learning Auto Encoder-Based Regions of Interest
por: Bowd, Christopher, et al.
Publicado: (2021)

Planning and analyzing clinical trials with composite endpoints
por: Rauch, Geraldine, et al.
Publicado: (2017)

Imaging endpoints for clinical trials in Alzheimer’s disease
por: Cash, David M, et al.
Publicado: (2014)

Understanding the Use of Composite Endpoints in Clinical Trials
por: McCoy, C. Eric
Publicado: (2018)

Efficacy Endpoints in Clinical Trials in Actinic Keratosis
por: Skov, Torsten, et al.
Publicado: (2018)

Phase I NT-501 Ciliary Neurotrophic Factor Implant Trial for Primary Open-Angle Glaucoma: Safety, Neuroprotection, and Neuroenhancement
por: Goldberg, Jeffrey L., et al.
Publicado: (2023)

Downstream Change of the Primary Endpoint in the ISCHEMIA Trial: the Elephant in the Room
por: Correia, Luis Cláudio Lemos, et al.
Publicado: (2018)

Erratum to: Immune maintenance in glaucoma: boosting the body’s own neuroprotective potential
por: Schwartz, Michal, et al.
Publicado: (2009)

Global optical coherence tomography measures for detecting the progression of glaucoma have fundamental flaws
por: Sun, Ashley, et al.
Publicado: (2021)

Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials
por: Yu, Jeffrey C., et al.
Publicado: (2022)

Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series
por: McDonald, James, et al.
Publicado: (2023)

A Coming of Age for Glaucoma Neuroprotection
por: Johnson, Thomas V.
Publicado: (2023)

Anesthetic Preconditioning as Endogenous Neuroprotection in Glaucoma
por: Chou, Tsung-Han, et al.
Publicado: (2018)

New perspectives of immunomodulation and neuroprotection in glaucoma
por: Skopiński, Piotr, et al.
Publicado: (2021)

The promise of neuroprotection by dietary restriction in glaucoma
por: Russo, Rossella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_baatom35bpvq9778q8l6s4egqa